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Background 
Definition of Immunoglobulin A nephropathy 
Immunoglobulin A nephropathy (IgAN) was first described by Berger and 
Hinglains in 1968. It is diagnosed by the predominance of IgA deposits, either alone or 
with IgG or IgM in the glomerular mesangium, with no evidence of other underlying 
disease [1]. So although the presence of glomerular hematuria and proteinuria suggests 
glomerulonephritis, renal biopsy is needed to confirm the diagnosis of IgAN.  
After immunohistological examination became widely accepted as a routine in 
the majority of institutions by the end of the 1960s, IgAN has been recognized as the 
most common cause of end-stage renal disease (ESRD) around the world—most 
markedly in Japan and other Asian countries, [2-4].  
 
Pathological findings in IgAN 
 As noted, histological evaluation is essential for diagnosis of IgAN, while 
mesangial hypercellularity and expansion of the mesangial matrix are the main 
histological changes with IgAN. In addition to these findings in the mesangium, various 
changes may be observed such as injury to podocytes and capillary loops as well as 
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tubular, interstitial and vascular lesions. 
 Although various classifications have been reported, the Oxford classification 
published in 2009 is now the most widely accepted worldwide [5]. Its scoring system— 
derived from Oxford’s analysis of patients’ renal outcome—is based on four biopsy 
findings: (1) the mesangial hypercellularity score, (2) segmental glomerulosclerosis, (3) 
endocapillary hypercellularity, and (4) tubular atrophy/interstitial fibrosis (Table 1). In 
Japan, however, a domestic histological classification based on a multicenter 
case-control study of IgAN was proposed in 2004 and published in 2013 [1, 6] (Tables 2 
A-C). It remains unclear which classification is more suitable for Japanese patients with 
IgAN. 
 
Pathogenesis of IgAN 
Pathogenesis of IgA nephropathy has not been fully elucidated, probably due to 
lack of adequate animal models. However it is well known that IgAN frequently recurs 
after kidney transplantation, suggesting that IgAN is a systemic disease in which the 
kidney sustains damage as an innocent bystander. Furthermore, in over 40% of patients 
with IgAN, a history of painless recurrent macroscopic hematuria is observed 1 to 2 
days following an infectious illness, most commonly pharyngitis or tonsillitis and less 
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often gastroenteritis or pneumonia [7, 8]. In IgAN, an increased fraction of circulatory 
IgA1 has a galactose deficiency in some carbohydrate side chains that are attached to 
the hinge-region segment of the heavy chain. Synthesis of poorly galactosylated IgA1, 
which is produced mainly in mucosal tissues, leads to the formation of immune 
complexes in the circulation or glomeruli. Although poorly galactosylate IgA1 is 
considered to be synthesized mainly by tonsillar B cells, and the serum level of the 
abnormal IgA1 was decreased after tonsillectomy in IgAN patients [9], recent study has 
suggested that the abnormal IgA1-producing plasma cells were also present in the bone 
marrow, not only in the mucosal tissues [10]. In turn, the complexed galactose-deficient 
IgA1 activates mesangial cells and leads to expansion of mesangial matrix, to mesangial 
hypercellularity, apoptosis, oxidative stress, activation of complement, and injury to 
podocytes [11]. It is generally thought that these renal injuries will lead to hypertension, 
proteinuria, hematuria, and reduced renal function.  
 
Epidemiology of IgAN 
In Japan, the incidence of IgAN is estimated to be 3.9 to 4.5 per 100,000 
persons per year. An estimated 33,000 persons have IgAN (95% confidence interval 
(CI): 28,000-37,000). IgAN has been found in every age group, though one third of 
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Japanese IgAN patients were diagnosed while teenagers [1]. The male to female ratio of 
IgAN varies among countries, reported as 1:1 in Asia, and 2:1 in North America [11]. 
Many studies in Asian and Western countries published in the 1980s to the 2010s 
showed very similar 10-year overall renal survival among IgAN patients—between 80% 
and 85%—no matter which one of many therapies was used [12, 13].  
Clinical predictors of IgAN at the time of initial examination were the amount 
of proteinuria, blood pressure levels, degree of renal dysfunction, and histological 
severity. And it is reported that a remission of urinary findings, defined as an 
improvement or disappearance of hematuria and proteinuria, is associated with 
improved renal prognosis. As a result, the remission of urinary findings is often used as 
a proxy outcome in trials, though the definition of the remission of urinary findings has 
not been fully confirmed [1, 14]. 
 
Treatment of IgAN 
Several registry data suggest that proteinuria < 1.0g/day, either at the time of 
biopsy or after therapy, leads to a better prognosis with IgAN [15, 16]. It has been 
reported that renin-angiotensin system inhibitors (RAS) can reduce proteinuria and slow 
the decline in the estimated glomerular filtration rate (eGFR) [14]. In addition, several 
 Junichi Hoshino Page 7 
 
studies, including controlled trials, reported that corticosteroid treatment was more 
effective than just RAS, especially for IgAN patients with proteinuria ≧1g/day and 
eGFR >50 ml/min/1.73m2 [17-20]. Based on these findings, the 2012 KDIGO Clinical 
Practice Guideline for Glomerulonephritis recommended use of corticosteroids as oral 
steroids (OS) or steroid pulse (SP) for patients with persistent proteinuria at that level, 
even after 3-6 months of optimal supportive care including RAS and blood pressure 
control [14].  
 Since episodes of macroscopic hematuria are not uncommon in patients with 
IgAN after bouts of recurrent tonsillitis, tonsillectomy is considered one of the treatment 
options for these patients, removing potential antigen stimuli [21]. The relationship 
between hematuria and tonsillar is supported by the findings that the abnormal 
polymeric IgA1 is mainly produced by mucosal tissues [9]. Nevertheless, in many 
countries—especially those in the West—it is considered unlikely that a dysregulated 
mucosal immune system in IgAN could be affected by tonsillectomy alone [22], 
because of the association between gastrointestinal mucosal immune systems and IgAN 
[23], and also because of the presence of the abnormal IgA1-producing plasma cells in 
the bone marrow[10]. For these reasons, tonsillectomy alone is not recommended in the 
2012 KDIGO clinical practice guideline [14], even though it is listed as a treatment 
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option in the Japanese clinical practice guideline for IgAN 2014 [1]. 
In 2001, Hotta et al. reported that tonsillectomy and steroid pulse (TSP) therapy 
was more effective in achieving clinical remission than SP, alone [24]; other such 
reports followed, including a controlled trial, suggesting good clinical remission rates in 
patients who received TSP [25-29]. In addition, a recent meta-analysis suggested a 
better clinical remission rate for patients with TSP than for those without tonsillectomy 
[30]. These reports showed that the effect of TSP on clinical remission of IgAN was 
superior to that of corticosteroid treatments, including SP; but the evidence showing the 
preventive effect of TSP on ESRD was not strong, mainly because this hard outcome 
takes a long follow-up with an inherently large drop-out rate, hence requires a 
particularly large sample size for stable analysis. In fact, a recent randomized controlled 
trial, comparing TSP with SP, concluded that TSP’s impact on renal function remains 
unknown [4].  
  
Study Objective 
As noted above, there is a distinct difference between the treatment of IgAN in 
Japan and the United States. In the KDIGO guideline, TSP therapy is not recommended 
routinely for treatment of IgAN whereas the Japanese Clinical Practice Guideline for 
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IgAN recommends it as grade C1. In addition, as written in the KDOGO guideline, 
there are no trials showing that RAS or other treatments actually decrease the risk of 
ESRD from IgAN. All these findings—sometimes inconclusive and even 
contradictory—impelled the present multicenter, long-term cohort study designed to 
investigate the comparative effect of TSP and other therapies in preventing ESRD. 
 
Methods 
Patient population 
 The data were obtained from medical records of patients treated at our four 
hospitals in the Tokyo metropolitan area March 1981-December 2013. The patients had 
biopsy-proven IgAN with an eGFR ≧30 ml/min/1.73m2, and were 18 years or older. 
Patients with a history of renal transplantation or of any other renal disease were 
excluded. 
 Pathological diagnosis had been performed by at least two observers, with 
histological grading of biopsy specimens evaluated using the Oxford IgAN 
classification [5] and the Japanese criteria published by the Japanese IgAN Study Group, 
with pathological grades (H-grades) I to IV representing, respectively, <25%, 25-49%, 
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50-74%, and ≧75% of glomeruli that exhibit cellular/fibrocellular crescents (active 
lesions) or fibrous crescents or global/segmental sclerosis (chronic lesions) [6]—or a 
combination thereof.  
Patients’ demographic data had been obtained at the time of renal biopsy. All 
laboratory data and medications—including serum albumin (Alb), serum creatinine, 
total cholesterol, hemoglobin (Hb), systolic and diastolic blood pressure, proteinuria, 
hematuria, body weight, use and dose of prednisone, use of RAS, anticoagulants, and/or 
antiplatelets—had been noted before treatment, at 3, 6, and 12 months after treatment, 
and every subsequent year until the end of follow-up. All laboratory values had been 
measured by the automated, standardized methods used in our hospitals within 24h after 
drawing blood samples. If the Jaffe method had been used to measure serum creatinine, 
the values were converted, for our analyses, to those for enzyme assays. Proteinuria was 
categorized into three groups: <0.5 g/gram creatinine (gCre) or urine dipstick with (-) or 
(±); 0.5-0.99 g/gCre or (+); and ≧1.0 g/gCre or (2+). Hematuria was categorized into 
four groups: <5/high power field (HPF) or urine dipstick with (-) or (±); 5-10/HPF or 
(+); 10-29/HPF or (2+); and ≧30/HPF or (3+). Renal-biopsy year was categorized as 
the 1980s, 1990s, or 2000s. The primary outcome of this study was initiation of dialysis 
as indication of ESRD, with all patients followed until ESRD, death, or end of 
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follow-up. The eGFR was calculated by the formula for Japanese patients devised by 
Matsuo et al. [31]. The study’s protocol was approved by institutional review boards in 
each hospital. 
 
Statistical analysis  
 We categorized patients into four groups—TSP, SP, OS, and RAS—based on 
their initial treatment and/or the treatment in use at >50% of their follow-ups. The TSP 
protocol was three courses of a 3-day pulse of methylprednisolone, 0.5g/day, 
administered 2-4 weeks after tonsillectomy, followed by oral corticosteroid at an initial 
dose of 30mg every other day, gradually tapered by 5mg every two months, then 
discontinued 12 months after the initial therapy. The original SP protocol was a 3-day 
pulse of methylprednisolone administered in months 1, 3, and 5 in addition to 0.5 mg/kg 
of oral prednisone every other day.  With both TSP and SP, however, the number of 
methylprednisolone pulses could be reduced to one or two courses depending on the 
patient’s condition or clinician’s preference. Data were summarized using proportions 
and means (±SD) as appropriate. Categorical variables were analyzed with the 
chi-squared or Fisher’s exact test, continuous variables compared using Student’s t-test, 
the Mann-Whitney U test, or ANOVA. Cumulative survival was estimated with 
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Kaplan-Meier survival curves, and compared by log-rank test. Cox proportional hazard 
models were used to obtain hazard ratios (HRs) and a 95% confidence interval (95% CI) 
for ESRD. In the Cox model 1, each HR was adjusted for the risk grade calculated by 
the IgA scoring system [32], medications (use of RAS, anticoagulants, and/or 
antiplatelets), and renal-biopsy year (RBY). In model 2, each HR was adjusted for sex, 
age, body mass index (BMI), eGFR, Alb, proteinuria, hematuria, blood pressure control, 
medications and RBY. In model 3, each HR was adjusted for model-2 factors plus 
pathological grade.  
To minimize selection bias for IgAN treatment, propensity score-matched 
analyses were performed to balance patients’ background characteristics, including 
treatment group, age, sex, eGFR, Alb, proteinuria, hematuria, Hb, blood pressure 
control, medications, RBY, and pathological grade. To estimate the propensity score, we 
used a logistic regression model for the choice of treatment as a function of the 
background characteristics detailed above. Each patient with RAS was matched with a 
patient with TSP, SP, and OS with nearest-neighbor matching on the logit scale. All 
analyses used Stata® SE version 13.1 (StataCorp, College Station, TX). 
 
Results 
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Characteristics of patients in this study 
 Of the 1,840 patients screened, 1,127 met the study criteria. Table 3 shows the 
characteristics of eligible IgAN patients who received TSP (n=209), SP (n=103), OS 
(n=300), and RAS, alone (n=515). Mean age was lower in the TSP and OS groups 
(p<0.01) than in the other two.  The proportion of chronic kidney disease (CKD), 
stages G1 and 2 (eGFR ≧60 ml/min/1.73m2), and proteinuria <1.0g/gCre was highest 
in the TSP group while the proportion of CKD, G3 (eGFR 30~59 ml/min/1.73m2), and 
proteinuria ≧1.0g/gCre was highest in the SP group (p<0.01). Of those in the TSP 
group, 65.1% also received RAS, as did 77.7% with SP, and 56.3% with OS (p<0.01). 
The mean initial dose of daily oral prednisolone with TSP, SP, and OS was, respectively, 
17±6mg, 26±13mg, and 28±11mg (p<0.001). Methylprednisolone pulse courses were 
reduced for 33% of the TSP patients, 66% with SP. The mean follow-up duration was 
8.3±6.4 years overall, 7.0±4.4 years with TSP, 6.6±5.4 with SP, 10.4±7.3 with OS, and 
8.0±6.4 with RAS, alone.  
 
Renal survival by decade 
 As shown in Table 4, overall 5, 10, 15, and 20-year survival was, respectively, 
93.3% (95% CI, 91.8-94.5), 85.3% (83.0-87.3), 78.2% (75.1-80.9), and 74.0% 
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(70.3-77.4). The 10-year survival with TSP of 96.3% (90.3-98.6) was significantly 
better than OS’s 79.7% (73.8-84.4) or RAS’s 84.8% (80.2-88.4) (p<0.05), that trend 
holding throughout the observation period. Survival with SP was better than with OS or 
RAS, but worse than with TSP. 
 Next, we compared renal survival of patients who received renal biopsy in the 
1980s, the 1990s, and 2000s (2000-present). Overall survival was, respectively, 79.6% 
(72.8-84.9), 84.6% (81.3-87.4), and 89.6% (86.0-92.4) (Table 4), indicating that renal 
outcome for IgAN patients improved over the decades. Interestingly, this survival rate 
was similar to that reported in European and Asian countries in the 1980s and 1990s 
(around 80-85%) [12]. Better renal outcome with TSP/SP may contribute to the overall 
improvement of renal outcome by decade. 
 
Renal survival with each treatment 
Comparing renal survival after renal biopsy for each group, 10- and 15-year 
survival was, respectively, with TSP, 96.3% (90.3-98.6) and 86.3% (68.8-94.3); with SP, 
85.7% (73.0-92.7) and 85.7% (73.0-92.7); with OS, 79.7% (73.8-84.4) and 71.3% 
(64.3-77.1); and with RAS, 84.8% (80.2-88.4) and 73.6% (64.3-77.1) (Table 4). The 
overall renal survival curve with TSP was significantly better than with other groups by 
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log rank: p=0.04 vs. SP; p<0.001 vs. OS or RAS (Figure 1a). When analyzing patients 
by proteinuria, the curves of all four groups were similar with proteinuria <1.0g/gCre or 
<0.5g/gCre, but when proteinuria was ≧1.0g/gCre, renal survival with TSP was better 
than with OS (p=0.02) or RAS (p=0.03) (Figure 1b-1d), and 10-year survival better with 
TSP than with SP (p=0.02) although, after 10 years, the curves of those two groups 
became similar—partially due to the limited number of patients with TSP and SP who 
were followed up >10 years. In addition, similar renal outcomes were observed when 
we divided patients treated with TSP and SP by the number of methylprednisolone 
pulses they received, whether one or two. However, the adjusted HR of patients treated 
with three or more pulses in model 3—with one or two as referent—was 0.09 (0.02-0.51, 
p=0.006), suggesting that treatment with three or more courses of pulse may be 
beneficial. 
Then we compared HRs of ESRD in each treatment group using Cox models 
with TSP as referent (Figure 2). With SP, the HR of ESRD was 2.10 (0.73-6.01) in 
model 1, 1.33 (0.44-4.04) in model 2, and 2.05 (0.60-7.03) in model 3. With OS, the HR 
of ESRD was 3.62 (1.51-8.65) in model 1, 3.56 (1.45-8.71) in model 2, and 4.19 
(1.47-11.99) in model 3. With RAS, the HR was 3.89 (1.63-9.30) in model 1, 3.64 
(1.48-8.96) in model 2, and 4.67 (1.66-13.12) in model 3. Although the HRs were not 
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significantly different between TSP and SP, these data suggested better renal prognosis 
for patients with TSP than with the other treatments, and were consistent throughout the 
models.  
Since use of TSP was wide-spread after the end of the ’90s, and many kinds of 
RAS appeared after 2000, we did sub-analyses of patients after the year 2000 (n=550). 
In these sub-analyses, the survival curve of TSP was significantly better than that of 
RAS (p<0.01), and showed a better trend than those of SP (p=0.13) and OS (p=0.11) 
(Figure 3). Also, in the Cox analyses, with TSP as referent, the overall HRs in model 2 
were, for SP, 0.95 (0.18-4.90), for OS, 4.32 (1.08-17.25), and for RAS, 5.41 
(1.43-20.44). The outcome of TSP was similar to that of SP, and significantly better than 
those of OS or RAS, which was consistent with our overall analyses.  
 
Comparison of treatments by renal function and proteinuria  
Next, to determine the best candidates for TSP, we analyzed the HR of each 
treatment by CKD stage and level of proteinuria with TSP as referent. As detailed in 
Figure 2, when proteinuria was ≧1.0g/gCre, the HR with TSP was significantly better 
than with OS or RAS—e.g., in model 2, respectively, 5.04 (1.44-17.67) and 7.23 
(1.98-26.40)—and showed a better trend than with SP, which was 2.99 (0.71-12.54), the 
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results consistent across the models.  However, for patients whose proteinuria was 
<1.0g/gCre—or whose CKD was G3—the HR with TSP was only slightly better than 
with OS or RAS and similar to that with SP, suggesting that tonsillectomy, in addition to 
SP, may not confer any additional benefit to those patients. 
 
Propensity score-matched analyses 
 Since we did not control the assignment of treatments, the treatment groups 
may have differences in their observed covariates that could lead to biased estimates of 
the treatment effect. So to minimize selection bias for choice of treatment, we 
performed propensity-score matching to balance patients’ background characteristics, 
including age, sex, eGFR, Alb, Hb, proteinuria, hematuria, blood pressure control, 
medications (use of RAS, anticoagulants or antiplatelets), and pathological grade. After 
matching, a similar distribution of characteristics was observed between TSP and other 
treatments (Table 5). As noted above, and shown in Figure 4, renal survival curves were 
slightly better with TSP than with SP up to10 years—especially in patients with 
proteinuria ≧1.0g/gCre (p=0.08)—but the difference became small after 10 years. The 
curves were significantly better with TSP than with OS or RAS, alone, especially in 
patients with proteinuria ≧1.0g/gCre.,  
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 Finally, we compared HRs for ESRD in each treatment group with Cox models. 
When compared with TSP as referent, HRs for ESRD in propensity score-matched 
patients were, for SP, 1.86 (0.59-5.91) in model 1, 1.28 (0.32-5.10) in model 2, and 3.79 
(0.69-20.83) in model 3; for OS, 2.93 (1.11-7.78) in model 1, 2.70 (0.92-7.91) in model 
2, and 3.80 (1.10-13.15) in model 3; for RAS, 7.41 (2.38-23.06) in model 1, 4.65 
(1.40-15.50) in model 2, and 18.51 (3.67-93.41) in model 3 (Table 6). So the HRs in the 
propensity score-matched population were very similar to those in the whole population, 
and those of TSP were the best among the four treatments in patients with proteinuria 
≧1.0 g/gCre, but similar to those of the other treatments in patients with 
proteinuria<1.0 g/gCre. 
 
Discussion 
 In this multicenter cohort study, we found that TSP was more strongly 
associated with lower HR of ESRD than SP, OS, or RAS in IgAN patients whose 
proteinuria was ≧1.0g/gCre, but not in patients with proteinuria <1.0g/gCre. In 
addition, we found that corticosteroid treatments (SP or OS) were better than RAS, 
alone, in patients with proteinuria ≧1.0 g/gCre, which is consistent with previous 
findings [17-20] and what is suggested in the 2012 KDIGO clinical practice guideline 
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[14].  
 There had been some reports showing that the effect of TSP on clinical 
remission of IgAN was superior to that of corticosteroid treatments, including SP 
[24-26]; but the evidence showing the preventive effect of TSP on ESRD was not strong, 
mainly because those studies lacked statistical power due to their short observation 
periods and limited number of participants. Recently, the first meta-analysis was 
reported showing that the effect of TSP on clinical remission was superior to that of SP, 
and showing the possible preventive effect of tonsillectomy on ESRD [30]. Although 
this was the first study suggesting the possible preventive effect of TSP on ESRD, the 
number of patients was limited (n=873) and diverse treatment procedures were included. 
To our knowledge, the present study is the largest ever conducted comparing treatments 
of IgAN with ESRD targeted as an outcome. Moreover, because our cohort, while 
large-scale, was treated at only four hospitals, treatment regimens were relatively well 
controlled compared with nationwide or meta-analysis cohorts. Interestingly, the HR of 
ESRD this study found when TSP was the treatment—with corticosteroid (SP or OS) as 
referent—was 0.19 (0.06-0.64), which is very similar to the reported pooled odds ratio 
of 0.25 (0.12-0.52) in the meta-analysis [30].  
 There are several new findings in this study. First, the patients who are most 
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probably the best candidates for TSP were identified. Our study showed that they were 
the patients with CKD G1 and G2 whose proteinuria was ≧1.0g/gCre; it also showed 
that TSP may be better than—and at least equal to—SP for patients with CKD G3 and 
proteinuria ≧1.0 g/gCre, and distinctly better than OS and RAS. Going by one finding 
in the meta-analysis cited above that suggested tonsillectomy to reduce the rate of 
ESRD [30], TSP may be more effective than SP, alone, in patients with IgAN. But, at 
this point, we cannot posit the superiority of TSP over SP because, in our study, the 
difference was not significant due to the wide range in HRs of 95% CI. And in patients 
with proteinuria <1.0g/gCre, the HRs with TSP, SP and OS were not significantly better 
than with RAS, again due to the wide range of 95% CI, suggesting that there is not 
enough evidence at this point to choose TSP over RAS for those patients. Second, our 
study showed an improvement in overall 10-year renal survival during the last three 
decades. In the 1980s, 1990s and 2000s, 10-year renal survival for our cohort was, 
respectively, 79.6% (72.8-84.9), 84.6% (81.3-87.4), and 89.5% (85.9-92.3). The reason 
for this may be that, in addition to improvement of the various treatment regimens (TSP, 
SP, etc.), the clinical trend toward total CKD management of IgAN has contributed to 
better renal prognosis in these patients because improvement of renal survival was also 
seen in within each treatment group. Therefore, third, a general trend in overall 10-year 
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renal survival with TSP may be inferred. Our multicenter large-scale cohort may 
represent patients in general who have undergone TSP because the numbers showing 
our patients’ condition and survival were very similar to those of other multicenter 
cohorts [4, 24, 25]. Note that our consistent results among analyses in the multiple 
models—adjusted for possible confounders—and among propensity score-matched 
analyses, show the robustness of our results.  
The benefit of TSP to patients with mild IgAN has not been confirmed. Our 
study did not find that TSP was superior to SP for these patients. Perhaps the effect of 
TSP over SP in patients with mild IgAN may be small because such patients have less 
immune abnormality associated with mucosa; or an inability to detect the difference 
between these two treatments may be inherent to the situation. Because the reported 
annual eGFR decline in patients with proteinuria <1.0 g/day was only -1.0 
ml/min/1.73m2/year (5), the instance of ESRD among such patients may be 
small—which, in our study, may have compromised detection of the difference between 
the TSP and SP groups. Recently, Komatsu et al. reported that TSP led to clinical 
remission more effectively than other treatments for IgAN patients with mild proteinuria 
(0.4-1.0g/day) [33]. In their study, the rate of clinical remission was significantly higher 
with TSP than with SP (71.7% vs. 44.4%). However, because the number of patients in 
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their study was very limited (especially in the SP group: n=9), and they merged patients 
who had received SP and OS in the same group, one must await larger studies to assess 
the efficacy of TSP over SP in patients with mild IgAN. Furthermore, although 
tonsillectomy is a relatively non-invasive operation, one patient in our cohort who 
received TSP experienced postoperative hemorrhage, requiring blood transfusion. And it 
has been reported that the rate of post-tonsillectomy hemorrhage was 2.3~7.7% [34, 35]. 
Therefore, at this point, SP might be the better choice for patients with mild IgAN. 
 There are several limitations to this study. First, selection biases in treatment 
may exist. Because of the nature of cohort studies, treatment protocols were not 
uniformly defined, which may obscure the actual effect of treatment. Indeed, younger 
patients with preserved renal function were more likely to receive TSP than other 
therapies—and more likely to receive it than were other groups—which may affect 
renal outcome in this study. However, the consistent results—including propensity 
score-matched analyses—may overcome this inherent disadvantage of cohort studies. 
Second, since the follow-up continued for many years, selection bias involving drop-out 
or trend of treatment in each era may exist. For example, steroid use was initiated in the 
1980s and TSP in the early 2000s. Although we adjusted by renal-biopsy years, and 
observed similar results in propensity score-matched analyses, one needs to be careful 
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in assessing these results. Finally, the 95% CIs of our HRs were relatively widely 
ranged. Although ESRD is considered the gold standard for renal-outcome studies, 
because it takes so long to become definite, this hard outcome needs a particularly large 
sample size for stable analysis, so its use may decrease study power in long follow-up 
studies with their inherently large drop-out rate. Some soft outcomes have been 
proposed as proxies for ESRD. But there is no direct evidence that, for instance, the 
doubling of serum creatinine or any other soft outcome is surely predictive of ESRD. 
Recently, the association of decline in eGFR with subsequent risk of ESRD was 
reported in the general CKD population [36], and this may be another possible factor in 
identifying the best candidates for TSP, though it is still unclear whether this association 
is same among different races or renal diseases. In any case, while ESDR remains the 
standard, analyses that involve an even larger IgAN population than ours are needed to 
confirm the best candidates for TSP in greater detail.  
 In conclusion, our multicenter large-scale cohort study demonstrated the 
effectiveness of TSP for patients with IgAN, and, for now, identified the best candidates 
for the treatment. If IgAN patients have CKD G1 or G2 with proteinuria ≧1.0g/gCre, 
TSP should be considered if they are not otherwise contraindicated for it, while SP, 
alone, may be the best option for patients with proteinuria <1.0g or CKD G3.  
 Junichi Hoshino Page 24 
 
 
Future plans 
For our study, we had to create a multicenter, large-sale cohort with 
biopsy-proven IgAN. Since the database of this cohort of course contains various 
clinical information in detail, it may be possible to use it to clarify unsolved clinical 
problems in treating IgAN patients. Indeed, as our next studies, we are now analyzing 
this cohort, focusing on the disappearance of proteinuria 1 or 2 years after treatment as 
an early detection marker of sustained renal function, and also focusing on the effect of 
blood pressure control during the treatment by stratifying CKD stage and level of 
proteinuria.  
With this cohort, it may also be possible to answer other questions, including 
what the best treatment option is for recurrent IgAN patients who once experienced 
complete remission, and which pathological classification—Oxford or Japanese—is 
better for predicting prognosis in IgAN patients. 
Our study also showed how little evidence there exists about IgAN patients 
with CKD G3. So we plan to use our collaborative network for a new randomized 
controlled study of IgAN patients with CKD G3 and proteinuria ≧1.0g/gCre to 
determine the most effective treatment option for them by comparing renal survival 
 Junichi Hoshino Page 25 
 
between patients who received SP versus OS when RAS and fish oil were used in both 
groups. Since these CKD G3 patients face the highest risk of ESRD, there is great 
urgency about identifying the optimum treatment strategy for them. 
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Table 1: Definition of pathological variables in the Oxford classification (Quoted from 
reference 5) 
Variable Definition Score 
Mesangial hypercellularity <4 Mesangial cells/mesangial area =0 
4-5 Mesangial cells/mesangial area =1 
6-7 Mesangial cells/mesangial area =2 
≧8 Mesangial cells/mesangial area =3 
The score is the mean score for all 
glomeruli 
M0 - ≦0.5 
M1 - ＞0.5a 
Segmental 
glomerulosclerosis 
Any amount of the tuft involved in 
sclerosis, but not involving the whole 
tuft or the presence of an adhesion 
S0 – absent 
S1 - present 
Endocapillary 
hypercellularity 
Hypercellularity due to increased 
number of cells within glomerular 
capillary lumina causing narrowing of 
the lumina 
E0 – absent 
E1 - present 
Tubular atrophy  
/ interstitial fibrosis 
Percentage of cortical area involving by 
the tubular atrophy or interstitial 
fibrosis, whichever is greater 
T0 – 0-25% 
T1 – 26-50% 
T2 - >50% 
a Mesangial score should be assessed in periodic acid-Schiff-stained sections. If more 
than half the glomeruli have more than three cells in a mesangial area, this is 
categorized as M1. Therefore, a formal mesangial cell count is not always necessary to 
derive the mesangial score. 
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Table 2: Histological classification in Japan (Quoted from reference 1) 
A. Histological grade 
Histological 
grade 
Percent glomeruli with 
pathological variables* 
predicting progression 
to ESRD 
Acute 
lesion only 
Acute and 
chronic lesion 
Chronic 
lesion only 
H-Grade I 0-24.9% A A/C C 
H-Grade II 25-49.9% A A/C C 
H-Grade III 50-74.9% A A/C C 
H-Grade IV >75% A A/C C 
*Acute lesion (A): cellular crescent, tuft necrosis, fibrocellular crescent 
 Chronic lesion (C): global sclerosis, segmental sclerosis, fibrous crescent 
 
B. Clinical grade 
Clinical grade Proteinuria (g/day) eGFR (ml/min/1.73m2) 
C-Grade I ＜0.5  ― 
C-Grade II ≧0.5 ≧60 
C-Grade III ≧0.5 ＜60 
 
C. Grading system for prediction progression to ESRD 
 H-Grade I H-Grade II H-Grade III 
C-Grade I Low Moderate High 
C-Grade II Moderate Moderate High 
C-Grade III High High Super High 
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Table 3: Baseline characteristics of patients who had biopsy-proven IgA nephropathy 
with estimated glomerular filtration rate (eGFR)≧30 ml/min/1.73m2 
    Total cohort 
Variables 
Total TSP SP OS RAS   p-valu
e (n=1,127) (n=209) (n=103) (n=300) (n=515)   
Age (years) 
 
44.1±15.5 36.4±11.7 46.2±18.3 40.6±15.7 48.8±14.4 
 
<0.001 
Sex (female %) 
 
43.4% 47.4% 52.4% 44.7% 39.2% 
 
0.03 
Mean eGFR (ml/min/1.73m2) 64.9±26.9 73.6±25.3 62.7±33.5 66.8±30.3 60.6±26.9 
 
<0.001 
CKD stage (eGFR) G1&2 (eGFR≧60) 76.0% 86.5% 64.1% 76.7% 74.5% 
 
<0.001 
  G3a (eGFR45-60) 15.4% 10.1% 16.5% 14.7% 17.7% 
 
  
  G3b (eGFR30-45) 8.6% 3.4% 19.4% 9.7% 7.8% 
 
  
Albumin (g/dl) 
 
3.7±0.6 3.6±0.4 3.4±0.6 3.6±0.7 3.8±0.5 
 
<0.001 
Total cholesterol (mg/dl) 205±50 196±39 213±59 214±64 202±40 
 
<0.001 
Hemoglobin (mg/dl) 
 
13.3±1.9 13.3±1.5 12.3±2.0 13.3±2.2 13.6±1.8 
 
<0.001 
Blood pressure systolic (mmHg) 129±19 125±17 131±18 127±18 133±19 
 
<0.001 
  
diastolic 
(mmHg) 
78±13 76±13 77±11 76±12 80±13 
 
<0.001 
Proteinuria (g/gCre) median [IQR] 
0.6 
[0.30-1.30] 
0.74 
[0.32-1.50] 
1.80 
[0.72-2.80] 
1.20 
[0.51-2.29] 
0.60 
[0.33-1.20]  
<0.001 
  <0.5 (g/gCre) 17.5% 22.4% 9.3% 12.1% 20.1% 
 
<0.001 
  
0.5-0.99 
(g/gCre) 
31.3% 36.3% 25.8% 23.2% 34.8% 
 
  
  ≧1.0 (g/gCre) 51.2% 41.3% 65.0% 64.6% 45.1% 
 
  
Hematuria <5/HPF or (-) 25.6% 16.5% 17.7% 22.2% 32.9% 
 
<0.001 
  5-10/HPF or (+) 15.0% 16.5% 13.7% 10.7% 17.2% 
 
  
  
10-29/HPF or 
(2+) 
27.3% 33.0% 24.5% 24.5% 27.2% 
 
  
  ≧30/HPF or (3+) 32.1% 34.0% 44.1% 42.6% 22.7% 
 
  
Pathological grade I 65.2% 68.0% 57.8% 69.6% 63.0% 
 
0.31 
(H-grade) II 21.1% 19.4% 27.5% 20.5% 20.9% 
 
  
 Junichi Hoshino Page 29 
 
  III 10.9% 9.7% 12.8% 8.2% 12.6% 
 
  
  IV 2.8% 2.9% 2.0% 1.7% 3.5% 
 
  
  Active lesion 29.8% 28.5% 51.1% 41.1% 18.7% 
 
<0.001 
Oxford 
classification 
  
  
M 14.5% 8.4% 25.3% 19.6% 12.0% 
 
<0.001 
E 28.3% 51.2% 52.6% 26.5% 18.0% 
 
<0.001 
S 63.9% 76.5% 80.7% 68.0% 52.7% 
 
<0.001 
T1/T2 24.3%/6.4% 24.3%/5.5% 28.3%/8.1% 21.5%/3.4% 25.1%/8.2% 
 
0.10 
Medication RAS inhibitors 79.9% 65.1% 77.7% 56.3% 100.0% 
 
<0.001 
  Anticoagulants 8.6% 1.0% 19.4% 16.3% 5.1% 
 
<0.001 
  Antiplatelets 54.8% 33.5% 50.5% 71.0% 54.8%   <0.001 
  PSL dose (mg/day) 24±11 17±6 26±13 28±11     <0.001 
 
Abbreviations: TSP, tonsillectomy plus steroid pulse therapy; SP, steroid pulse therapy; 
OS, oral steroid therapy; RAS, inhibitors of the renin-angiotensin system; IQR, 
interquartile range; HPF, high-power field.  
 
  
 Junichi Hoshino Page 30 
 
Table 4: Renal outcomes among treatment groups 
Variables 
Total TSP SP OS RAS   p-val
ue (n=1,127) (n=209) (n=103) (n=300) (n=515)   
  
 
  
     
  
Mean follow-up 
years 
8.3±6.4 7.0±4.4 6.6±5.4 10.4±7.3 8.0±6.4 
 
<0.00
1 
  
 
  
     
  
Proportion of 
ESRD  
13.6% 3.4% 8.7% 22.0% 13.8% 
 
<0.00
1 
  
 
  
     
  
5-year renal 
survival (%) 
93.3 
[91.8-94.5] 
99.3 
[94.9-99.9] 
90.6 
[81.1-95.5] 
89.8 
[85.4-93.0] 
93.1 
[90.1-95.2]  
<0.00
1 
10-year renal 
survival (%) 
85.3 
[83.0-87.3] 
96.3 
[90.3-98.6] 
85.7 
[73.0-92.7] 
79.7 
[73.8-84.4] 
84.8 
[80.2-88.4]  
<0.00
1 
15-year renal 
survival (%) 
78.2 
[75.1-80.9] 
86.3 
[68.8-94.3} 
85.7 
[73.0-92.7] 
71.3 
[64.3-77.1] 
73.6 
[67.0-79.1]  
<0.00
1 
20-year renal 
survival (%) 
74.0 
[70.3-77.4] 
86.3 
[68.8-94.3} 
85.7 
[73.0-92.7] 
65.3 
[56.8-72.5] 
69.1 
[60.6-76.2]  
<0.00
1 
  
 
  
     
  
10-year renal 
survival (%) 
  
     
  
1980s 
 
79.6 
[72.8-84.9] 
n/a n/a 
71.1 
[51.6-83.9] 
80.7 
[56.3-92.3]  
0.89 
1990s 
 
84.6 
[81.3-87.4] 
100 
85.2 
[60.2-95.1] 
78.6 
[70.6-84.6] 
86.7 
[80.3-91.1]  
0.02 
2000s   
89.6 
[86.0-92.4] 
95.3 
[87.9-98.3] 
87.8 
[74.2-94.5] 
87.1 
[76.5-93.2] 
83.3 
[75.3-88.8] 
  0.002 
Abbreviations: TSP, tonsillectomy plus steroid pulse therapy; SP, steroid pulse therapy; 
OS, oral steroid therapy; RAS, inhibitors of the renin-angiotensin system; ESRD, end- 
stage renal disease; n/a, not applicable. 
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Table 5: Baseline characteristics of propensity score-matched pairs of patients, TSP and. 
other treatment groups. 
(a) Propensity score-matching, TSP and RAS 
Variables 
Total TSP RAS p-value 
(n=254) (n=127) (n=127)   
Age (years) 
 
41.1±12.3 40.0±11.7 42.3±12.7 0.14 
Gender (female %) 
 
39.8% 41.7% 37.8% 0.90 
Mean eGFR (ml/min/1.73m2) 67.7±25.9 67.1±25.9 68.4±25.9 0.69 
CKD stage (eGFR) G1&2 (eGFR≧60) 80.3% 81.1% 79.5% 0.14  
  G3a (eGFR45-60) 14.6% 15.0% 14.2%   
  G3b (eGFR30-45) 5.1% 3.9% 6.3%   
Albumin (g/dl) 
 
3.5±0.5 3.5±0.4 3.5±0.6 0.97 
Total cholesterol (mg/dl) 199±39 199±41 199±39 0.97 
Hemoglobin (mg/dl) 13.4±1.8 13.3±1.6 13.5±1.9 0.51 
Blood pressure systolic (mmHg) 128±17 128±16 128±17 97 
  diastolic (mmHg) 78±13 78±13 78±12 0.33 
Proteinuria (g/gCre) median [IQR] 0.74 [0.38-1.51] 0.86 [0.44-1.64] 0.62 [0.35-1.32] 0.06 
  <0.5 (g/gCre) 18.1% 15.8% 20.5% 0.35 
  0.5-1.0 (g/gCre) 37.4% 35.4% 39.4%   
  >1.0 (g/gCre) 44.5% 48.8% 40.2%   
Hematuria <5/HPF or (-) 22.1% 17.3% 26.8% 0.32  
  5-10/HPF or (+) 15.0% 16.5% 13.4%   
  10-29/HPF or (2+) 32.3% 33.1% 31.5%   
  ≧30/HPF or (3+) 30.7% 33.1% 28.4%   
Pathological grade I 59.1% 57.5% 60.6% 0.55 
(H-grade) II 22.4% 25.2% 19.7%   
  III 15.4% 13.4% 17.3%   
  IV 3.2% 3.9% 2.4%   
  Active lesion 28.4% 31.4% 25.3% 0.33 
Oxford M 14.8% 10.3% 19.4% 0.04 
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  E 34.9% 45.0% 30.2% 0.25 
  S 67.0% 80.8% 54.4% 0.003 
  T1/T2 27.3%/8.8% 29.6%/7.2% 25.0%/10.5% 0.53 
Medication RAS inhibitors 100.0% 100.0% 100.0% 1.00 
  Anticoagulants 0.0% 0.0% 0.0% 1.00 
  Anti-platelets 35.8% 37.0% 34.7% 0.70 
 
(b) Propensity score-matching, TSP and SP 
Variables 
Total TSP SP p-value 
(n=190) (n=95) (n=95)   
Age (years) 45.1±14.6 44.5±11.0 45.8±17.5 0.54 
Sex (female %) 50.5% 48.4% 52.6% 0.56 
Mean eGFR (ml/min/1.73m2) 62.4±28.7 61.3±23.6 63.5±33.1 0.60 
CKD stage (eGFR) G1&2 (eGFR≧60) 71.1% 76.0% 66.3% 0.03  
  G3a (eGFR45-60) 16.3% 17.9% 14.7%   
  G3b (eGFR30-45) 12.6% 6.3% 19.0%   
Albumin (g/dl) 3.4±0.5 3.5±0.4 3.4±0.6 0.24 
Total cholesterol (mg/dl) 208±50 203±38 214±60 0.16 
Hemoglobin (mg/dl) 12.7±1.8 12.9±1.6 12.5±2.0 0.07 
Blood pressure systolic (mmHg) 130±18 129±17 131±18 0.59 
  diastolic (mmHg) 78±12 79±14 77±11 0.34 
Proteinuria (g/gCre) median [IQR] 1.13 [0.60-2.3] 0.95 [0.54-1.79] 1.60 [0.67-2.70] 0.005 
  <0.5 (g/gCre) 10.5% 11.6% 9.5% 0.26 
  0.5-1.0 (g/gCre) 31.1% 35.8% 26.3%   
  >1.0 (g/gCre) 58.4% 52.6% 64.2%   
Hematuria <5/HPF or (-) 19.5% 21.1% 17.9% 0.25  
  5-10/HPF or (+) 17.9% 21.1% 14.7%   
  10-29/HPF or (2+) 26.3% 28.4% 24.2%   
  ≧30/HPF or (3+) 36.3% 29.5% 43.2%   
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Pathological grade I 59.5% 60.0% 59.0% 0.79 
(H-grade) II 25.3% 25.3% 25.3%   
  III 12.1% 10.5% 13.7%   
  IV 3.2% 4.2% 2.1%   
  Active lesion 39.1% 24.0% 53.1% 0.001 
Oxford M 17.8% 9.7% 26.1% 0.004 
  E 51.5% 62.5% 48.1% 0.31 
  S 81.0% 82.1% 80.3% 0.83 
  T1/T2 31.0%/7.6% 35.9%/7.6% 26.1%/7.6% 0.34 
Medication RAS inhibitors 80.5% 84.2% 76.8% 0.20 
  Anticoagulants 11.1% 2.1% 20.0% <0.001 
  Antiplatelets 45.3% 41.1% 49.5% 0.24 
      
(c) Propensity score-matching, TSP and OS 
Variables 
Total TSP OS p-value 
(n=394) (n=197) (n=197)   
Age (years) 
 
38.7±14.1 36.7±11.9 40.7±15.7 0.01 
Sex (female %) 
 
46.5% 47.7% 45.2% 0.61 
Mean eGFR (ml/min/1.73m2) 71.2±27.6 74.1±25.5 68.4±29.3 0.04 
CKD stage (eGFR) G1&2 (eGFR≧60) 82.0% 86.8% 77.2% 0.01  
  G3a (eGFR45-60) 11.7% 10.2% 13.2%   
  G3b (eGFR30-45) 6.4% 3.1% 9.6%   
Albumin (g/dl) 
 
3.7±0.6 3.6±0.4 3.7±0.7 0.24 
Total cholesterol (mg/dl) 202±52 195±39 209±61 0.01 
Hemoglobin (mg/dl) 13.3±1.9 13.3±1.5 13.3±2.2 0.92 
Blood pressure systolic (mmHg) 125±17 125±17 126±17 0.34 
  diastolic (mmHg) 76±13 76±13 76±12 0.67 
Proteinuria (g/gCre) median [IQR] 0.83 [0.35-1.57] 0.69 [0.30-1.22] 1.00 [0.42-1.66] 0.003 
  <0.5 (g/gCre) 19.3% 22.8% 15.7% 0.001 
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  0.5-1.0 (g/gCre) 31.0% 36.6% 25.4%   
  >1.0 (g/gCre) 49.8% 40.6% 58.9%   
Hematuria <5/HPF or (-) 20.3% 17.3% 23.4% 0.05  
  5-10/HPF or (+) 14.2% 16.8% 11.7%   
  10-29/HPF or (2+) 28.7% 33.0% 24.4%   
  ≧30/HPF or (3+) 36.8% 33.0% 40.6%   
Pathological grade I 70.6% 69.0% 72.1% 0.71 
(H-grade) II 19.0% 18.8% 19.3%   
  III 8.1% 9.6% 6.6%   
  IV 2.3% 2.5% 2.0%   
  Active lesion 34.7% 28.5% 42.3% 0.01 
Oxford M 14.5% 8.8% 20.4% 0.001 
  E 38.5% 50.0% 33.7% 0.07 
  S 71.0% 75.9% 67.5% 0.20 
  T1/T2 21.3%/4.5% 23.8%/4.7% 18.7%/4.3% 0.45 
  
 
  
  
  
Medication RAS inhibitors 64.2% 64.5% 64.0% 0.92 
  Anticoagulants 4.3% 1.0% 7.6% 0.001 
  Antiplatelets 45.9% 31.0% 60.9% <0.001 
Abbreviations: TSP, tonsillectomy plus steroid pulse therapy; SP, steroid pulse therapy; 
OS, oral steroid therapy; RAS, inhibitors of the renin-angiotensin system; IQR, 
interquartile range; HPF, high-power field.  
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Table 6: Hazard ratios (HRs) of end-stage renal disease in propensity score-matched 
cohorts by treatment regimens, proteinuria, and CKD stages 
 Model 1 Model 2 Model 3 
TSP 1.00 (referent) 1.00 (referent) 1.00 (referent) 
SP 1.86 [0.59-5.91] 1.28 [0.32-5.10] 3.79 [0.69-20.83] 
OS 2.93 [1.11-7.76] 2.70 [0.92-7.91] 3.80 [1.10-13.15] 
RAS 7.41 [2.38-23.06] 4.65 [1.40-15.50] 18.51 [3.67-93.41] 
 
Each HR was adjusted in model 1, for IgA scoring system, medications (use of RAS, 
anticoagulants, and/or antiplatelets), and year of renal-biopsy; in model 2, for sex, age, 
body mass index (BMI), eGFR, Alb, proteinuria, hematuria, blood pressure, medications 
and year of renal biopsy; and in model 3, for factors in model 2 plus pathological grade. 
Abbreviations: Upro, proteinuria g/gCre; TSP, tonsillectomy plus steroid pulse therapy; 
SP, steroid pulse therapy; OS, oral steroid therapy; and RAS, inhibitors of 
renin-angiotensin system; eGFR, estimated glomerular filtration rate. 
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Figure 1: Renal survival by treatment group, level of proteinuria, and renal function 
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Abbreviations: Upro, proteinuria g/gCre; TSP, tonsillectomy plus steroid pulse therapy; 
SP, steroid pulse therapy; OS, oral steroid therapy; and RAS, inhibitors of 
renin-angiotensin system; eGFR, estimated glomerular filtration rate.  
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Figure 2: Hazard ratios (HRs) of end-stage renal disease by treatment regimen, 
proteinuria, and CKD stages. 
 
Each HR was adjusted in model 1, for IgA scoring system, medications (use of RAS, 
anticoagulants, and/or antiplatelets), and year of renal-biopsy; in model 2, for sex, age, 
body mass index (BMI), eGFR, Alb, proteinuria, hematuria, blood pressure, medications 
and year of renal biopsy; and in model 3, for factors in model 2 plus pathological grade. 
Abbreviations: Upro, proteinuria g/gCre; TSP, tonsillectomy plus steroid pulse therapy; 
SP, steroid pulse therapy; OS, oral steroid therapy; and RAS, inhibitors of 
renin-angiotensin system; eGFR, estimated glomerular filtration rate.  
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Figure 3: Renal survival by treatment group in 2000’s 
 
The p-values were calculated by log-rank test. 
Abbreviations: TSP, tonsillectomy plus steroid pulse therapy; SP, steroid pulse therapy; 
OS, oral steroid therapy; and RAS, inhibitors of renin-angiotensin system. 
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Figure 4: Comparison of renal survival in propensity score-matched cohorts by 
treatment. 
 
The p-values were calculated by log-rank test. 
Abbreviations: Upro, proteinuria g/gCre; TSP, tonsillectomy plus steroid pulse therapy; 
SP, steroid pulse therapy; OS, oral steroid therapy; and RAS, inhibitors of 
renin-angiotensin system. 
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